Both AstraZeneca and MSD have tied lucrative licensing deals for two of LaNova’s oncology assets in recent years.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

European shares ended slightly lower on Monday, with tariff-sensitive auto stocks down after U.S. President Donald Trump's ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The research service ...

AstraZeneca's Phase 3 trial showed baxdrostat lowered systolic blood pressure in treatment-resistant hypertension with a ...

A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy ...

"Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a statistically significant and clinically meaningful reduction in mean-seated ...

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Deutsche Bank cuts London Stock Exchange price target to 12,700 (12,900) pence - ...

In recent months, IonQ has made several acquisitions in order to boost its technology stack and intellectual property, buying ...

Eight years after it was established partly by AstraZeneca, Dizal Pharmaceuticals has gained its first FDA approval, winning an accelerated nod for Zegfrovy (sunvozertinib) to become the only ...